Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 2/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818159 | 0.83 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2383149 | 0.83 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13162557 | 0.81 | ALDH1A1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29158062 | 0.81 | ALDH1A1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28316970 | 0.81 | POLB (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL403705 | 0.81 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7809866 | 0.80 | TSHR (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13199477 | 0.79 | ALDH1A1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11139348 | 0.79 | ALDH1A1 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28861659 | 0.78 | FFAR1 (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121709-A1 | PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS | PFIZER INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024051717-A1 | COMPOUND AS PLK1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117658987-A | Compounds as PLK1 inhibitors, and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023078410-A1 | COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF | 上海美志医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-20220298172-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3976623-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020242960-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2020-11-26 | — | — | US | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8143284-B2 | 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBVIE INC. | 2008-05-08 | — | — | US | disclosed |
| EP-0685478-B1 | QUINOLINE DERIVATIVES | UBE INDUSTRIES (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5591752-A | LEUKOTRIENE ANTAGONIST, ANTIALLERGEN, ANTIINFLAMMATORY AGENT, DIBENZ(B,E)OXEPINE | UBE INDUSTRIES, LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| EP-0685478-A1 | QUINOLINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298172-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HSP90B1, EIF4EBP1, SERPINA6 | CA12 4258/4885CA1 4537/4885CA2 4348/4885 |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | HSP90B1, EIF4EBP1, SERPINA6 | CA12 4258/4885CA1 4537/4885CA2 4348/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | CA12 2486/4885CA1 2675/4885CA2 493/4885 |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HSP90B1, EIF4EBP1, SERPINA6 | CA12 4258/4885CA1 4537/4885CA2 4348/4885 |
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP11, PARP2 | CA12 4343/4885CA1 3980/4885CA2 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.